Business
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided additional results from its Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent
About this update from Aclaris Therapeutics, Inc.
[{"type":"image","alt":"Aclaris Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aclaris Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/863f11ac89f9dbe84886691262d6e9f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtMq4w0NL5RX6oHluykk3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3Ng--/https://media.zenfs.com/en/globenewswire.com/863f11ac89f9dbe84886691262d6e9f8","width":300,"height":126}},"lazy":false},{"type":"text","content":"- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life -","length":162,"tagName":"p"},{"type":"text","content":"WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided additional results from its Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of ITK and Janus kinase 3 (JAK3), presented in an electronic poster at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.","length":495,"tagName":"p"},{"type":"text","content":"“We have continued to achieve important milestones for our potential best-in-class ITK inhibitor franchise, including the presentation of additional positive results from our open-label Phase 2a trial of ATI-2138 at this year’s AAD meeting,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “Beyond the previously disclosed efficacy measures, patients receiving ATI-2138 experienced substantial improvements in disease severity, itch, affected percentage of body surface area, and disease-related quality of life measures. In total, these results further validate the strong mechanistic rationale for the use of ATI-2138 in a wide variety of immuno-inflammatory diseases.”","length":678,"tagName":"p"},{"type":"text","content":"2026 American Academy of Dermatology (AAD) Annual Meeting","length":57,"tagName":"p"},{"type":"text","content":"In an ePoster (74636) entitled, “Results from an Open-Label Phase 2 Trial of ATI-2138, an Investigational Oral Covalent Inhibitor of Interleukin-2-Inducible T Cell Kinase (ITK) And Janus Kinase 3 (JAK3), in Patients wit...